



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/501683/2016

European Medicines Agency decision

P/0218/2016

of 15 August 2016

on the acceptance of a modification of an agreed paediatric investigation plan for elobixibat (EMEA-001484-PIP01-13-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0218/2016

of 15 August 2016

on the acceptance of a modification of an agreed paediatric investigation plan for elobixibat (EMA-001484-PIP01-13-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0053/2014 issued on 7 March 2014,

Having regard to the application submitted by Elobix AB on 1 April 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 June 2016, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for elobixibat, film-coated tablet, age-appropriate formulation, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Elobix AB, Arvid Wallgrens Backe 20, 413 46 – Gothenburg, Sweden.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/258793/2016

London, 24 June 2016

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001484-PIP01-13-M01

Scope of the application

Active substance(s):

Elobixibat

Condition(s):

Treatment of chronic constipation

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Elobix AB

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Elobix AB submitted to the European Medicines Agency on 1 April 2016 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0053/2014 issued on 7 March 2014.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 26 April 2016.



Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

Waiver

1.1. Condition

Treatment of chronic constipation

The waiver applies to:

- the paediatric population from birth to less than 6 months;
- for film-coated tablet and age-appropriate formulation, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of chronic constipation

2.1.1. Indication(s) targeted by the PIP

Treatment of functional constipation

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet and age appropriate formulation

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Development of an age-appropriate formulation
Non-clinical	2	Dose-ranging juvenile toxicity study in rats Definitive juvenile toxicity study of Elobixibat in the rat
Clinical	1	Double-blinded, randomized, placebo-controlled study to evaluate safety, efficacy and pharmacokinetics of elobixibat for 4 weeks followed by a 20-week open-label extension phase in children 6 months to less than 18 years of age with functional constipation

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2024
Deferral for one or more studies contained in the paediatric investigation plan:	Yes